{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,2]],"date-time":"2025-10-02T10:25:09Z","timestamp":1759400709005,"version":"3.37.3"},"reference-count":32,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,3,1]],"date-time":"2025-03-01T00:00:00Z","timestamp":1740787200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,3,1]],"date-time":"2025-03-01T00:00:00Z","timestamp":1740787200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,3,1]],"date-time":"2025-03-01T00:00:00Z","timestamp":1740787200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2025,3,1]],"date-time":"2025-03-01T00:00:00Z","timestamp":1740787200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2025,3,1]],"date-time":"2025-03-01T00:00:00Z","timestamp":1740787200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2025,3,1]],"date-time":"2025-03-01T00:00:00Z","timestamp":1740787200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2025,3,1]],"date-time":"2025-03-01T00:00:00Z","timestamp":1740787200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100002383","name":"King Saud University","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100002383","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100011665","name":"King Saud University Deanship of Scientific Research","doi-asserted-by":"publisher","award":["RSPD2024R754"],"award-info":[{"award-number":["RSPD2024R754"]}],"id":[{"id":"10.13039\/501100011665","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Analytical Biochemistry"],"published-print":{"date-parts":[[2025,3]]},"DOI":"10.1016\/j.ab.2024.115741","type":"journal-article","created":{"date-parts":[[2024,12,3]],"date-time":"2024-12-03T16:57:36Z","timestamp":1733245056000},"page":"115741","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"special_numbering":"C","title":["Development and validation of a sensitive and fast bioanalytical LC-MS\/MS assay for the quantitation of venetoclax and azacitidine in Rat Plasma: Application to pharmacokinetic study"],"prefix":"10.1016","volume":"698","author":[{"given":"Manal","family":"El-Gendy","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9152-0735","authenticated-orcid":false,"given":"Mohamed","family":"Hefnawy","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sarah","family":"Alrubia","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Abdulaziz","family":"Alnasser","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Amsha","family":"Alsegiani","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yousef Bin","family":"Jardan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Adel","family":"El-Azab","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alaa","family":"Abdel-Aziz","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mohamed","family":"Attwa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Emad","family":"Alsarhani","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.ab.2024.115741_bib1","doi-asserted-by":"crossref","first-page":"615","DOI":"10.1002\/ajh.27246","article-title":"Long-term follow-up of VIALE-A: venetoclax and azacitidine in chemotherapy-ineligible untreated acute myeloid leukemia","volume":"99","author":"Pratz","year":"2024","journal-title":"Am. J. Hematol."},{"year":"2022","series-title":"Acute Myeloid Leukemia Treatment (PDQ\u00ae)-Patient Version","key":"10.1016\/j.ab.2024.115741_bib2"},{"key":"10.1016\/j.ab.2024.115741_bib4","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2021.708943","article-title":"Editorial: novel combination therapies for the treatment of solid cancers","volume":"11","author":"Ayoub","year":"2021","journal-title":"Front. Oncol."},{"key":"10.1016\/j.ab.2024.115741_bib5","doi-asserted-by":"crossref","DOI":"10.7554\/eLife.50036","article-title":"A curative combination cancer therapy achieves high fractional cell killing through low cross-resistance and drug additivity","volume":"8","author":"Palmer","year":"2019","journal-title":"Elife"},{"key":"10.1016\/j.ab.2024.115741_bib6","first-page":"350","article-title":"Two drugs are better than one. A short history of combined therapy of ovarian cancer","volume":"19","author":"Bukowska","year":"2015","journal-title":"Contemp. Oncol."},{"key":"10.1016\/j.ab.2024.115741_bib7","doi-asserted-by":"crossref","first-page":"4303","DOI":"10.2174\/1381612823666170703164114","article-title":"Protein kinase inhibitors as therapeutic drugs in AML: advances and challenges","volume":"23","author":"Ling","year":"2017","journal-title":"Curr. Pharmaceut. Des."},{"key":"10.1016\/j.ab.2024.115741_bib8","doi-asserted-by":"crossref","first-page":"1047","DOI":"10.1021\/acs.jmedchem.1c00963","article-title":"Small molecule kinase inhibitor drugs (1995\u20132021): medical indication, pharmacology, and synthesis","volume":"65","author":"Ayala-Aguilera","year":"2022","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ab.2024.115741_bib9","doi-asserted-by":"crossref","first-page":"857","DOI":"10.1093\/jjco\/hyab018","article-title":"Venetoclax in combination with azacitidine in Japanese patients with acute myeloid leukaemia: phase 1 trial findings","volume":"28","author":"Taniguchi","year":"2021","journal-title":"Jpn. J. Clin. Oncol."},{"key":"10.1016\/j.ab.2024.115741_bib10","doi-asserted-by":"crossref","first-page":"226","DOI":"10.3109\/10428194.2014.910657","article-title":"Ex vivo activity of BCL-2 family inhibitors ABT-199 and ABT-737 combined with 5-azacytidine in myeloid malignancies","volume":"56","author":"Bogenberger","year":"2015","journal-title":"Leuk. Lymphoma"},{"key":"10.1016\/j.ab.2024.115741_bib11","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1038\/leu.2017.243","article-title":"Enhancing venetoclax activity in acute myeloid leukemia by co-targeting MCL1","volume":"32","author":"The","year":"2018","journal-title":"Leukemia"},{"key":"10.1016\/j.ab.2024.115741_bib13","doi-asserted-by":"crossref","first-page":"617","DOI":"10.1056\/NEJMoa2012971","article-title":"Azacitidine and venetoclax in previously untreated acute myeloid leukemia","volume":"383","author":"DiNardo","year":"2020","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.ab.2024.115741_bib14","doi-asserted-by":"crossref","first-page":"749","DOI":"10.1007\/s00277-023-05109-5","article-title":"Venetoclax plus azacitidine compared with intensive chemotherapy as induction for patients with acute myeloid leukemia: retrospective analysis of an electronic medical record database in the United States","volume":"102","author":"Zeidan","year":"2023","journal-title":"Ann. Hematol."},{"key":"10.1016\/j.ab.2024.115741_bib15","doi-asserted-by":"crossref","first-page":"1680","DOI":"10.1038\/leu.2008.145","article-title":"A pilot pharmacokinetic study of oral azacitidine","volume":"22","author":"Garcia-Manero","year":"2008","journal-title":"Leukemia"},{"key":"10.1016\/j.ab.2024.115741_bib16","doi-asserted-by":"crossref","first-page":"889","DOI":"10.1038\/leu.2015.265","article-title":"Efficacy and safety of extended dosing schedules of CC-486 (oral azacitidine) in patients with lower-risk myelodysplastic syndromes","volume":"30","author":"Garcia-Manero","year":"2016","journal-title":"Leukemia"},{"key":"10.1016\/j.ab.2024.115741_bib17","doi-asserted-by":"crossref","first-page":"440","DOI":"10.1002\/phar.1371","article-title":"A phase I study in patients with solid or hematologic malignancies of the dose proportionality of subcutaneous Azacitidine and its pharmacokinetics in patients with severe renal impairment","volume":"34","author":"Laille","year":"2014","journal-title":"Pharmacotherapy"},{"key":"10.1016\/j.ab.2024.115741_bib18","doi-asserted-by":"crossref","first-page":"3906","DOI":"10.1200\/JCO.2005.07.450","article-title":"Pharmacokinetics of 5-azacitidine administered with phenylbutyrate in patients with refractory solid tumors or hematologic malignancies","volume":"23","author":"Rudek","year":"2005","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.ab.2024.115741_bib19","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1016\/j.jchromb.2004.09.012","article-title":"Quantification of 5-azacytidine in plasma by electrospray tandem mass spectrometry coupled with high-performance liquid chromatography","volume":"813","author":"Zhao","year":"2004","journal-title":"J. Chromatogr. B"},{"key":"10.1016\/j.ab.2024.115741_bib20","doi-asserted-by":"crossref","first-page":"494","DOI":"10.1002\/bmc.3562","article-title":"A robust and rapid liquid chromatography tandem mass spectrometric method for the quantitative analysis of 5-azacytidine","volume":"30","author":"Anders","year":"2016","journal-title":"Biomed. Chromatogr."},{"key":"10.1016\/j.ab.2024.115741_bib21","doi-asserted-by":"crossref","first-page":"342","DOI":"10.3390\/molecules19010342","article-title":"Development of a supercritical fluid chromatography-tandem mass spectrometry method for the determination of azacitidine in rat plasma and its application to a bioavailability study","volume":"27","author":"Li","year":"2013","journal-title":"Molecules"},{"key":"10.1016\/j.ab.2024.115741_bib22","doi-asserted-by":"crossref","first-page":"1607","DOI":"10.3390\/molecules27051607","article-title":"Quantification of venetoclax for therapeutic drug monitoring in Chinese acute myeloid leukemia patients by a validated UPLC-MS\/MS method","volume":"28","author":"Yang","year":"2022","journal-title":"Molecules"},{"key":"10.1016\/j.ab.2024.115741_bib23","doi-asserted-by":"crossref","first-page":"392","DOI":"10.5530\/jyp.2018.10.87","article-title":"Evaluation of deuterium-labeled internal standard for the measurement of venetoclax by HPLC-ESI -tandem mass spectrometry","volume":"10","author":"Inturi","year":"2018","journal-title":"J. Young Pharm."},{"key":"10.1016\/j.ab.2024.115741_bib24","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1080\/10826076.2024.2352846","article-title":"Rapid and highly sensitive HILIC-HPLC based analytical assay method for quantification of azacitidine and venetoclax in a single run","volume":"47","author":"More","year":"2024","journal-title":"J. Liq. Chromatogr. Relat. Technol."},{"key":"10.1016\/j.ab.2024.115741_bib25","doi-asserted-by":"crossref","first-page":"1583","DOI":"10.1093\/carcin\/5.12.1583","article-title":"The tumorigenicity of 5-azacytidine in the male Fischer rat","volume":"5","author":"Brian","year":"1984","journal-title":"Carcinogenesis"},{"journal-title":"Health Saf. Regul.","article-title":"Australian public assessment report for venetoclax","year":"2017","key":"10.1016\/j.ab.2024.115741_bib26"},{"key":"10.1016\/j.ab.2024.115741_bib27","doi-asserted-by":"crossref","first-page":"1424","DOI":"10.1128\/AAC.43.6.1424","article-title":"Species differences in the proportion of plasma lipoprotein lipid carried by high-density lipoproteins influence the distribution of free and liposomal nystatin in human, dog, and rat plasma","volume":"43","author":"Ramaswamy","year":"1999","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.ab.2024.115741_bib29","doi-asserted-by":"crossref","first-page":"306","DOI":"10.1016\/j.cmpb.2010.01.007","article-title":"PKSolver: an add-in program for pharmacokinetic and pharmacodynamic data analysis in Microsoft. Excel","volume":"99","author":"Zhang","year":"2010","journal-title":"Comput. Methods Progr. Biomed."},{"key":"10.1016\/j.ab.2024.115741_bib30","doi-asserted-by":"crossref","DOI":"10.1016\/j.jpba.2021.114108","article-title":"Rapid and sensitive LC-MS\/MS method for the enantioanalysis of verapamil in rat plasma using superficially porous silicaisopropyl-cyclofructan 6 chiral stationary phase after SPE: application to a stereoselective pharmacokinetic study","volume":"201","author":"Hefnawy","year":"2021","journal-title":"J. Pharm. Biomed. Anal."},{"article-title":"Australian public assessment report for azacytidine","year":"2013","series-title":"Health Safty Regulation","key":"10.1016\/j.ab.2024.115741_bib31"},{"key":"10.1016\/j.ab.2024.115741_bib33","doi-asserted-by":"crossref","first-page":"484","DOI":"10.1002\/jcph.821","article-title":"Pharmacokinetics of venetoclax, a novel BCL-2 inhibitor, in patients with relapsed or refractory chronic lymphocytic leukemia or non-hodgkin lymphoma","volume":"57","author":"Salem","year":"2017","journal-title":"J. Clin. Pharmacol."},{"key":"10.1016\/j.ab.2024.115741_bib34","doi-asserted-by":"crossref","DOI":"10.1016\/j.jchromb.2020.122176","article-title":"Development and validation of a sensitive UHPLC-MS\/MS analytical method for venetoclax in mouse plasma, and its application to pharmacokinetic studies","volume":"1152","author":"Eisenmann","year":"2020","journal-title":"J. Chromatogr. B"},{"key":"10.1016\/j.ab.2024.115741_bib35","doi-asserted-by":"crossref","first-page":"1335","DOI":"10.1002\/jcph.730","article-title":"Evaluation of rifampin's transporter inhibitory and CYP3A inductive effects on the pharmacokinetics of venetoclax, a BCL-2 inhibitor: results of a single- and multiple-dose study","volume":"56","author":"Agarwal","year":"2016","journal-title":"J. Clin. Pharmacol."},{"key":"10.1016\/j.ab.2024.115741_bib36","doi-asserted-by":"crossref","first-page":"1355","DOI":"10.1002\/jcph.741","article-title":"Effect of low- and high-fat meals on the pharmacokinetics of venetoclax, a selective first-in-class BCL-2 inhibitor","volume":"56","author":"Salem","year":"2016","journal-title":"J. Clin. Pharmacol."}],"container-title":["Analytical Biochemistry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0003269724002859?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0003269724002859?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,1,5]],"date-time":"2025-01-05T05:58:14Z","timestamp":1736056694000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0003269724002859"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,3]]},"references-count":32,"alternative-id":["S0003269724002859"],"URL":"https:\/\/doi.org\/10.1016\/j.ab.2024.115741","relation":{},"ISSN":["0003-2697"],"issn-type":[{"type":"print","value":"0003-2697"}],"subject":[],"published":{"date-parts":[[2025,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Development and validation of a sensitive and fast bioanalytical LC-MS\/MS assay for the quantitation of venetoclax and azacitidine in Rat Plasma: Application to pharmacokinetic study","name":"articletitle","label":"Article Title"},{"value":"Analytical Biochemistry","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ab.2024.115741","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"115741"}}